Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

[1]  C. Orkin,et al.  Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Yee,et al.  A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid‐Reducing Agents , 2019, Journal of clinical pharmacology.

[3]  M. Bickel,et al.  Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial , 2019, Journal of acquired immune deficiency syndromes.

[4]  A. Antinori,et al.  Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. , 2019, International journal of antimicrobial agents.

[5]  J. Butterton,et al.  Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans , 2019, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  K. Yee,et al.  Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir , 2019, Antimicrobial Agents and Chemotherapy.

[7]  L. V. Van Bortel,et al.  Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions , 2019, Antimicrobial Agents and Chemotherapy.

[8]  K. Yee,et al.  Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1 , 2019, Antimicrobial Agents and Chemotherapy.

[9]  Meihong Lin,et al.  In Vitro Evaluation of the Drug Interaction Potential of Doravirine , 2019, Antimicrobial Agents and Chemotherapy.

[10]  V. Calvez,et al.  Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients , 2018, The Journal of antimicrobial chemotherapy.

[11]  P. Sax,et al.  543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults , 2018, Open Forum Infectious Diseases.

[12]  M. Bickel,et al.  LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial , 2018, Open Forum Infectious Diseases.

[13]  P. Sax,et al.  LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial , 2018, Open Forum Infectious Diseases.

[14]  P. Sax,et al.  Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Rachel Liu,et al.  Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects , 2018, Journal of clinical pharmacology.

[16]  R. Preston,et al.  Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics , 2018, Antimicrobial Agents and Chemotherapy.

[17]  P. Sax,et al.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. , 2018, The lancet. HIV.

[18]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[19]  K. Yee,et al.  A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers , 2017, Clinical Drug Investigation.

[20]  K. Lasseter,et al.  Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics , 2017, Journal of clinical pharmacology.

[21]  M. Rizk,et al.  A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir , 2017, Clinical Pharmacokinetics.

[22]  K. Yee,et al.  Effect of Gender and Age on the Relative Bioavailability of Doravirine: Results of a Phase I Trial in Healthy Subjects , 2017, Antiviral therapy.

[23]  J. Brejda,et al.  The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects , 2017, Clinical Drug Investigation.

[24]  K. Yee,et al.  The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects , 2017, Clinical Drug Investigation.

[25]  M. Rizk,et al.  Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir , 2017, Clinical Pharmacokinetics.

[26]  K. Yee,et al.  Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study , 2016, Antimicrobial Agents and Chemotherapy.

[27]  M. Lai,et al.  Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects , 2016, Antimicrobial Agents and Chemotherapy.

[28]  Min Xu,et al.  Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations , 2016, Antimicrobial Agents and Chemotherapy.

[29]  J. Wagner,et al.  A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals , 2015, AIDS.

[30]  L. V. Van Bortel,et al.  Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects , 2015, Antiviral therapy.

[31]  D. Hazuda,et al.  In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways , 2014, Antimicrobial Agents and Chemotherapy.

[32]  Sébastien Gagné,et al.  Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. , 2014, Bioorganic & medicinal chemistry letters.

[33]  Jason Burch,et al.  In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor , 2013, Antimicrobial Agents and Chemotherapy.

[34]  B. Clotet,et al.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial , 2011, The Lancet.

[35]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[36]  C Gibson,et al.  Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design , 2011, Clinical pharmacology and therapeutics.

[37]  Roland Marquet,et al.  HIV-1 reverse transcriptase inhibitors , 2007, Applied Microbiology and Biotechnology.